Literature DB >> 32053069

DPepH3, an Improved Peptide Shuttle for Receptor-independent Transport across the Blood-Brain Barrier.

Marco Calvinho Cavaco1, Javier Valle Garcia2, Ruben Diogo Marques da Silva3, João Domingos Galamba Correia3, Miguel Augusto Rico Botas Castanho1, David Andreu Martinez2, Vera Luísa Santos Neves1.   

Abstract

The use of peptides as drug carriers across the blood-brain barrier (BBB) has increased significantly during the last decades. PepH3, a seven residue sequence (AGILKRW) derived from the α-helical domain of the dengue virus type-2 capsid protein, translocates across the BBB with very low toxicity. Somehow predictably from its size and sequence, PepH3 is degraded in serum relatively fast. Among strategies to increase peptide half-life (t1/2), use of the enantiomer (wholly made of D-amino acid residues) can be quite successful if the peptide interacts with a target in non-stereospecific fashion. Here we report that aGilkrw (DPepH3), the enantiomer of PepH3, has a much longer t1/2. We also confirm that BBB translocation is receptor-independent, which fully validates the enantiomer strategy chosen. Moreover, the cell internalization step that initiates transcytosis follows a macropinocytosis pathway. Taken together, our results place DPepH3 at the forefront of a second generation of BBB shuttles with excellent translocation and internalization properties, safety, and improved stability. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Adsorption-mediated transcytosis; Blood-brain barrier; D-amino acids; Macropinocytosis; PepH3; Peptide shuttles; Stability

Year:  2020        PMID: 32053069     DOI: 10.2174/1381612826666200213094556

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

1.  Customized blood-brain barrier shuttle peptide to increase AAV9 vector crossing the BBB and augment transduction in the brain.

Authors:  Xintao Zhang; Zheng Chai; Amanda Lee Dobbins; Michelle S Itano; Charles Askew; Zhe Miao; Hongqian Niu; R Jude Samulski; Chengwen Li
Journal:  Biomaterials       Date:  2021-12-31       Impact factor: 12.479

2.  The HIV-1 Matrix Protein p17 Does Cross the Blood-Brain Barrier.

Authors:  Francesca Caccuri; Vera Neves; Arnaldo Caruso; Miguel Castanho; Lurdes Gano; João D G Correia; Maria Cristina Oliveira; Pietro Mazzuca
Journal:  J Virol       Date:  2021-10-20       Impact factor: 6.549

3.  Targeting Zika Virus with New Brain- and Placenta-Crossing Peptide-Porphyrin Conjugates.

Authors:  Toni Todorovski; Diogo A Mendonça; Lorena O Fernandes-Siqueira; Christine Cruz-Oliveira; Giuseppina Guida; Javier Valle; Marco Cavaco; Fernanda I V Limas; Vera Neves; Íris Cadima-Couto; Sira Defaus; Ana Salomé Veiga; Andrea T Da Poian; Miguel A R B Castanho; David Andreu
Journal:  Pharmaceutics       Date:  2022-03-29       Impact factor: 6.525

4.  The antimetastatic breast cancer activity of the viral protein-derived peptide vCPP2319 as revealed by cellular biomechanics.

Authors:  Filipa D Oliveira; Marco Cavaco; Tiago N Figueira; Javier Valle; Vera Neves; David Andreu; Diana Gaspar; Miguel A R B Castanho
Journal:  FEBS J       Date:  2021-11-07       Impact factor: 5.622

5.  Conjugation of a Blood Brain Barrier Peptide Shuttle to an Fc Domain for Brain Delivery of Therapeutic Biomolecules.

Authors:  Marco Cavaco; Silvia Frutos; Paula Oliete; Javier Valle; David Andreu; Miguel A R B Castanho; Miquel Vila-Perelló; Vera Neves
Journal:  ACS Med Chem Lett       Date:  2021-09-02       Impact factor: 4.632

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.